Yoshihiro Miyahara
Tsu, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
MAGE-A4 pMHC-targeted CAR-T cells exploiting TCR machinery exhibit significantly improved in vivo function while retaining antigen specificity.
Journal: Journal for immunotherapy of cancer
Published: October 27, 2024
Evaluation of MAGE-A4 expression in breast cancer and its impact on prognosis.
Journal: Cancer science
Published: September 18, 2024
Exploring for the Development of Personalized Cancer Immunotherapy
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: May 23, 2023
Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma: A Phase I/II Clinical Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 16, 2023
Preclinical evaluation of a novel CAR-T therapy utilizing a scFv antibody highly specific to MAGE-A4p230-239/HLA-A∗02:01 complex.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: April 25, 2023
Fully closed cell sorter for immune cell therapy manufacturing.
Journal: Molecular therapy. Methods & clinical development
Published: March 30, 2023
A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.
Journal: International journal of cancer
Published: September 18, 2022
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.
Journal: Journal for immunotherapy of cancer
Published: June 02, 2022
IL-17A Is the Critical Cytokine for Liver and Spleen Amyloidosis in Inflammatory Skin Disease.
Journal: International journal of molecular sciences
Published: March 29, 2022
Prognostic significance of NY-ESO-1 antigen and PIGR expression in esophageal tumors of CHP-NY-ESO-1-vaccinated patients as adjuvant therapy.
Journal: Cancer immunology, immunotherapy : CII
Published: August 30, 2021
Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients.
Journal: Cancer immunology, immunotherapy : CII
Published: December 10, 2020
Last Updated: 09/26/2026